EW

EW tops Q3 earnings and revenue estimates as strong structural heart therapy sales drive margin expansion and prompt higher 2026 guidance.

Heavy AI capex hit free cash flows at Alphabet and Meta, while Microsoft and Amazon faced mounting concerns over compressed margins, search cannibalization, and agentic commerce disruption. With Apple reporting on an unusual Monday schedule, nine S&P 500 firms confirmed delayed reporting dates, a historical indicator of potential bad news ahead. This marks the second week of Q3 earnings season, with 2,465 companies expected to report and overall S&P 500 EPS growth holding at a robust 29.5%.

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

Edwards Lifesciences NYSE: EW highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of the PASCAL system and the PROGRESS trial evaluating TAVR in certain patients with moderate aortic stenosis. Get Edwards Lifesciences alerts:Sign UpCLASP IITR meets six-month primary endpoint Charlie Davidson, chief of cardiology and medical director of the Bluhm Cardiovascular Institute and global co-principal investigator of CLASP IITR, said the trial met its six-month composite primary endpoint.

Edwards Lifesciences Corp. EW is scheduled to report third-quarter 2026 results on Nov. 4, after the market closes.

Beyond analysts' top-and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.

Edwards Lifesciences gets a buy for my initial rating. Strengths come from recent FDA approvals, a niche portfolio serving the cardiology segment, and impressive operating margins and operating cash flow. EW's price return vs. key benchmarks showed weakness this year.

Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived versio.